CDK7 and neoplasm: To further explore the therapeutic potential of SE-driven transcriptional dependencies in G3-MB, we evaluated the inhibitory effects of targeting SE complex components (BRD4 or CDK7) in combination with targeting SE-associated tumor-dependent effector genes.